Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse large B-cell lymphomas with plasmablastic differentiation.

Julie Teruya-Feldstein1

  • 1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. feldstej@mskcc.org

Current Oncology Reports
|August 11, 2005
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL) with plasmablastic features is a diverse group of diseases. Understanding these distinct entities and their molecular drivers is crucial for accurate diagnosis and treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Nature genetics·2025
Same author

Regression of smoldering myeloma with treatment of Gaucher disease.

Blood advances·2024
Same author

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.

Blood advances·2024
Same author

NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss.

EMBO reports·2022
Same author

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.

Nature medicine·2021
Same author

Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factor-Mutant Neoplasms.

Cancer discovery·2021

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) with plasmablastic differentiation exhibits significant clinical heterogeneity.
  • This heterogeneity suggests distinct clinicopathologic entities within the spectrum of plasmablastic DLBCL.
  • Several subtypes are recognized, including oral mucosa type, PBL with plasmacytic differentiation, primary effusion lymphoma (PEL), and HHV-8 associated DLBCL.

Purpose of the Study:

  • To review recent clinicopathologic insights into DLBCL with plasmablastic differentiation.
  • To discuss molecular players involved in terminal B-cell or plasma cell differentiation.
  • To explore the potential roles of these molecules in disease pathogenesis.

Main Methods:

  • Literature review of recent evidence on DLBCL with plasmablastic differentiation.

Related Experiment Videos

  • Analysis of clinicopathologic characteristics and molecular findings.
  • Discussion of differential diagnoses including Castleman disease-associated PBL and myeloma/plasmacytoma.

    • Main Results:

    • DLBCL with plasmablastic features encompasses diverse entities with varying phenotypes.
    • Some entities exhibit mature B-cell (CD20 positive) markers despite plasma cell morphology.
    • Other entities are associated with specific viruses (KSHV/HHV-8) or conditions (multicentric Castleman disease).

    Conclusions:

    • Accurate classification of DLBCL with plasmablastic differentiation is essential due to clinical heterogeneity.
    • Understanding the molecular basis of terminal B-cell differentiation is key to elucidating pathogenesis.
    • Further research into these distinct entities may improve diagnostic accuracy and therapeutic strategies.